Shan Hu, Zhen Guo, and Chenze Li review coronary artery disease advancements
Recent advancements in coronary artery disease drug development are reshaping patient care through novel lipid-lowering agents, targeted anti-inflammatory therapies, and precision medicine frameworks. According to a state-of-the-art review published in Cardiovascular Innovations and Applications (CVIA) in 2026 by Shan Hu, Zhen Guo, and Chenze Li, these innovations expand therapeutic options for high-risk populations by integrating … Read more